-
Theravance's drug grips the bacterial membrane more tightly than vancomcyin, enabling it to kill faster.
FORBES: On The Cover/Top Stories
-
Theravance shares soared almost 14 percent in premarket trading 45 minutes before the market opening.
WSJ: Elan enters $1B royalty deal with Theravance
-
Leading the group were shares of Theravance (THRX), up about 15.8% and shares of Affymax (AFFY) up about 11.8% on the day.
FORBES: Santarus
-
At Theravance, Merck alum Roy Vagelos lured former Merck chemist Burton Christensen, co-inventor of three antibiotics at Merck, to come out of retirement in 1998 to help create new antibiotics.
FORBES: Germ Warfare
-
Among the largest underlying components of XBI, in trading today Onyx Pharmaceuticals, Inc. ( NASD: ONXX) is off about 0.1%, Pharmacyclics, Inc. ( NASD: PCYC) is off about 0.6%, and Theravance Inc ( NASD: THRX) is lower by about 0.8%.
FORBES: SPDR S&P Biotech ETF Experiences Big Outflow